Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.
暂无分享,去创建一个
Jeroen Aerssens | Gaston Picchio | Inge Dierynck | Anne Ghys | J. Aerssens | J. Sullivan | Sandra De Meyer | Tara L Kieffer | G. Picchio | Kim Thys | James C Sullivan | I. Dierynck | S. De Meyer | A. Ghys | K. Thys | T. Kieffer
[1] A. Lok,et al. 1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) , 2013 .
[2] O. Weiland,et al. Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.
[3] Tara L. Kieffer,et al. Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.
[4] Ann D. Kwong,et al. VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.
[5] Christoph Sarrazin,et al. Resistance to direct antiviral agents in patients with hepatitis C virus infection. , 2010, Gastroenterology.
[6] Tara L. Kieffer,et al. Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials , 2012, PloS one.
[7] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[8] Tara L. Kieffer,et al. Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples , 2013, Virology Journal.
[9] D. Hazuda,et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. , 2013, Virology.
[10] Michael Adler,et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.
[11] Tara L. Kieffer,et al. Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir , 2012, PloS one.
[12] Tara L. Kieffer,et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Martin Kircher,et al. High‐throughput DNA sequencing – concepts and limitations , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.
[14] K. Metzner,et al. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure , 2011 .
[15] S. Zeuzem,et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[16] G. Vaughan,et al. Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected Individuals , 2011, Journal of Clinical Microbiology.
[17] E. Lavezzo,et al. Applications of Next-Generation Sequencing Technologies to Diagnostic Virology , 2011, International journal of molecular sciences.
[18] F. Sato,et al. Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing , 2011, PloS one.
[19] Tara L. Kieffer,et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial , 2012, Hepatology.
[20] F. Zoulim,et al. LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY , 2010 .
[21] R. Paredes,et al. Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects , 2011, PloS one.
[22] Margaret C. Linak,et al. Sequence-specific error profile of Illumina sequencers , 2011, Nucleic acids research.
[23] S. Bennett. Solexa Ltd. , 2004, Pharmacogenomics.